BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 27021755)

  • 1. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
    Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
    Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
    Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
    Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
    Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
    Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dutch Tariff for the Five-Level Version of EQ-5D.
    M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
    Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
    Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
    Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valuing EQ-5D-5L health states 'in context' using a discrete choice experiment.
    Cole A; Shah K; Mulhern B; Feng Y; Devlin N
    Eur J Health Econ; 2018 May; 19(4):595-605. PubMed ID: 28569351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies.
    Shah K; Mulhern B; Longworth L; Janssen MF
    Value Health; 2016 Jan; 19(1):53-9. PubMed ID: 26797236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time trade-off and ranking exercises are sensitive to different dimensions of EQ-5D health states.
    Rand-Hendriksen K; Augestad LA
    Value Health; 2012; 15(5):777-82. PubMed ID: 22867789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating an EQ-5D-5L Value Set for China.
    Luo N; Liu G; Li M; Guan H; Jin X; Rand-Hendriksen K
    Value Health; 2017 Apr; 20(4):662-669. PubMed ID: 28408009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
    Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
    Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot discrete choice experiment to explore preferences for EQ-5D-5L health states.
    Norman R; Cronin P; Viney R
    Appl Health Econ Health Policy; 2013 Jun; 11(3):287-98. PubMed ID: 23649892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration?
    Mulhern B; Norman R; Lorgelly P; Lancsar E; Ratcliffe J; Brazier J; Viney R
    Pharmacoeconomics; 2017 Apr; 35(4):439-451. PubMed ID: 27873226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating quality weights for EQ-5D (EuroQol-5 dimensions) health states with the time trade-off method in Taiwan.
    Lee HY; Hung MC; Hu FC; Chang YY; Hsieh CL; Wang JD
    J Formos Med Assoc; 2013 Nov; 112(11):699-706. PubMed ID: 24183199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
    Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
    Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.